Dabo Medical announced that the company held a board meeting on October 12, 2026 to review and pass a bill to adjust the share repurchase plan, adjusting the total repurchase capital from no less than 130 million yuan and no more than 260 million yuan to no less than 140 million yuan and no more than 280 million yuan. The upper limit of the repurchase price is 49.41 yuan/share. The repurchase of shares is used to implement the equity incentive plan, with the exception of the total capital. As of the date of disclosure of the announcement, the company had repurchased a total of 6.21,17 million shares, accounting for 1.5003% of the total share capital, and a total transaction amount of 260 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.